Article info

Download PDFPDF

Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients
  1. Correspondence to:
    Dr M E Ebelin
    Novartis Pharma AG, WSJ-210-340, CH-4002 Basel, Switzerland; marieeve.ebelinpharma.novartis.com
View Full Text

Citation

Allen BR, Lakhanpaul M, Morris A, et al
Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients

Publication history

  • Accepted March 4, 2003
  • First published November 11, 2003.
Online issue publication 
November 11, 2003

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.